MedTrace Logo

Study With Oral Isovue in Abdominopelvic CT

NCT04453059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2023-02-08

No results posted yet for this study

Summary

This is a retrospective clinical study with prospectively designed blinded evaluation of CT images in adult and pediatric patients who underwent CT examinations of the abdomen and pelvis and were orally administered a solution of Isovue-300 to opacify the GI tract to distinguish it from adjacent abdominal and pelvic structures. The study will collect already existing data, such as demographic data, adverse events and CT images, for all chronologically enrolled patients who meet the inclusion/exclusion criteria prospectively defined in this protocol

Conditions

  • Patients Requiring Abdominopelvic CT With Oral Administration of Contrast

Interventions

DRUG

Iopamidol

Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-07-01
Completion
2022-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453059 on ClinicalTrials.gov